Clinical Trial Update: Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating denosumab for osteoporosis associated with systemic mastocytosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Systemic Mastocytosis

Drugs mentioned

• Prolia (denosumab)
• Xgeva (denosumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Osteoporosis, Systemic Mastocytosis | Phase 3 | Status: COMPLETED